NCT06059885 2023-09-29
Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC
Beijing 302 Hospital
Phase 2 Unknown
Clinical Trials
4 trialsNCT05422183 2022-06-16
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
Phase 2 Unknown
NCT04760431 2021-06-02
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT02687425 2016-02-22
SESPI
Tongji Hospital
Phase 2 Unknown